Differences in CD44s expression in HNSCC tumours of different areas within the oral cavity

Biomedical Papers

Volumn 157, Issue 4, 2013, Pages 280-283

  Krump, Michal ^a   Ehrmann, Jiri ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

CD44s; Immunohistochemistry; Oral cancer; Sub sites

Indexed keywords

CD44 PROTEIN, HUMAN; HERMES ANTIGEN;

BIOSYNTHESIS; COMPARATIVE STUDY; FEMALE; HEAD AND NECK TUMOR; HUMAN; MALE; METABOLISM; MOUTH TUMOR; SQUAMOUS CELL CARCINOMA;

ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MOUTH NEOPLASMS;

EID: 84890399682     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2012.107     Document Type: Article

References (16)

1. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61:1303-13.
2. Haynes BF, Liao HX, Patton KL. The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. Cancer Cells 1991;3:347-50.
3. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45.
4. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol 1999;52:189-96.
5. Boldrup L, Coates PJ, Laurell G, Nylander K. Differences in p63 expression in SCCHN tumours of different sub-sites within the oral cavity. Oral Oncol 2011;47:861-5.
6. Boldrup L, Coates PJ, Gu X, Nylander K. DeltaNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J Pathol 2007;213:384-91.
7. Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope 2004;114:2063-72.
8. Thurfjell N, Coates PJ, Uusitalo T, Mahani D, Dabelsteen E, Dahlqvist A, Sjöström B, Roos G, Nylander K. Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol 2004;25:27-35.
9. Weber A, Bellmann U, Bootz F, Wittekind C, Tannapfel A. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck. Int J Cancer 2002;99:22-8.
10. Esteban F, Bravo JJ, González-Moles MA, Bravo M, Ruiz-Avila I, Gil-Montoya JA. Adhesion molecule CD44 as a prognostic factor in laryngeal cancer. Anticancer Res 2005;25:1115-21.
11. Gonzalez-Moles MA, Bravo M, Ruiz-Avila I, Esteban F, Rodriguez-Archilla A, Gonzalez-Moles S, Arias B. Adhesion molecule CD44 as a prognostic factor in tongue cancer. Anticancer Res 2003;23:5197-202.
12. Stoll C, Baretton G, Soost F, Terpe HJ, Domide P, Löhrs U. Prognostic importance of the expression of CD44 splice variants in oral squamous cell carcinomas. Oral Oncol 1999; 35:484-9.
13. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104:973-8.
14. Zhang Z, Filho MS, Nör JE. The biology of head and neck cancer stem cells. Oral Oncol 2012;48:1-9.
15. Ailles L, Prince M. Cancer stem cells in head and neck squamous cell carcinoma. Methods Mol Biol 2009;568:175-93.
16. Kokko LL, Hurme S, Maula SM, Alanen K, Grénman R, Kinnunen I, Ventelä S. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol 2011;47:510-6.